Indicated for Acute and chronic anxiety states and as an adjunctive therapy in patients with refractory epilepsyassociated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or old.
The mechanism of action for clobazam, involves potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABA receptor.
For doses above 5 mg/day administer in two divided doses,Patients ≤30 kg body weight: Initiate at 5 mg daily and titrate as tolerated up to 20 mg daily, Patients >30 kg body weight: Initiate at 10 mg daily and titrate as tolerated up to 40 mg daily.
Yogazam is contraindicated in patients with a history of hypersensitivity to the drug or its ingredients.
Somnolence or Sedation: Monitor for central nervous system (CNS) depression. Withdrawal: Symptoms may occur with rapid dose reduction or discontinuation. Serious Dermatological Reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis): Discontinue at first sign of rash unless the rash is clearly not drug-related. Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behaviors.
Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Clobazam is secreted in milk; a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Safety and effectiveness in patients less than 2 years of age have not been established.
Drugs metabolized by CYP2D6: Lower doses of these drugs may be required when used concomitantly with Yogazam Strong or Moderate CYP2C19 Inhibitors: Dosage adjustment of Yogazam may be necessary; Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
The most common adverse events areconstipation, somnolence or sedation, pyrexia, lethargy.
Doctors
Nurses
PRODUCT DETAILS VIEW ALL PRODUCTS